Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3526 |
|
| Actual shortage: | 229 (6%) | |
| Anticipated shortage: | 3 (0%) | |
| Avoided shortage: | 11 (0%) | |
| Resolved: | 3283 (93%) | |
Discontinuation Reports |
366 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 342 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
143 (4%) |
|
Overdue reports |
32 (13%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-RANITIDINE TABLET 150MG | 150MG | TABLET | Resolved | 2017-11-21 | 2018-09-29 | 29983 |
| APO-RANITIDINE TABLET 150MG | 150MG | TABLET | Actual shortage | 2019-09-18 | 2019-09-18 | 94174 |
| APO-RANITIDINE TABLET 300MG | 300MG | TABLET | Resolved | 2017-05-04 | 2017-07-22 | 8889 |
| APO-RANITIDINE TABLET 300MG | 300MG | TABLET | Resolved | 2017-06-08 | 2017-07-26 | 12364 |
| APO-RANITIDINE TABLET 300MG | 300MG | TABLET | Resolved | 2017-08-30 | 2017-10-31 | 20645 |
| APO-RANITIDINE TABLET 300MG | 300MG | TABLET | Actual shortage | 2019-09-18 | 2019-09-18 | 94177 |
| APO-RASAGILINE | 0.5MG | TABLET | Resolved | 2017-03-11 | 2017-03-28 | 438 |
| APO-RASAGILINE | 0.5MG | TABLET | Resolved | 2017-03-11 | 2017-03-28 | 441 |
| APO-RASAGILINE | 0.5MG | TABLET | Resolved | 2017-03-11 | 2017-03-28 | 469 |
| APO-RASAGILINE | 1MG | TABLET | Resolved | 2017-03-11 | 2017-03-28 | 472 |
| APO-RASAGILINE | 1MG | TABLET | Resolved | 2017-05-04 | 2018-04-05 | 8892 |
| APO-RASAGILINE | 0.5MG | TABLET | Resolved | 2017-06-27 | 2017-11-13 | 14011 |
| APO-RASAGILINE | 1MG | TABLET | Resolved | 2019-02-24 | 2019-08-30 | 76743 |
| APO-RASAGILINE | 0.5MG | TABLET | Resolved | 2019-06-12 | 2019-08-30 | 86327 |
| APO-RASAGILINE | 1MG | TABLET | Resolved | 2020-06-24 | 2020-09-21 | 118775 |
| APO-RASAGILINE | 1MG | TABLET | Resolved | 2020-10-21 | 2020-12-29 | 126777 |
| APO-RASAGILINE | 0.5MG | TABLET | Resolved | 2021-12-17 | 2022-09-01 | 151360 |
| APO-RASAGILINE | 1MG | TABLET | Resolved | 2021-12-17 | 2022-09-01 | 151367 |
| APO-RASAGILINE | 1MG | TABLET | Resolved | 2023-03-16 | 2023-04-27 | 187244 |
| APO-RASAGILINE | 1MG | TABLET | Resolved | 2023-11-17 | 2023-12-08 | 210743 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |